Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 37 to 41 of 41 entries
Sorted by: Best Match Show Resources per page
Role of beta-blocker therapy in the postmyocardial infarction patient with and without left ventricular dysfunction consensus guideline.

Critical pathways in cardiology

Fonarow GC, Abraham WT, Gheorghiade M, Cannon CP, Sackner-Bernstein JD, Udelson JE, Konstam MA.
PMID: 18340127
Crit Pathw Cardiol. 2003 Dec;2(4):239-46. doi: 10.1097/01.hpc.0000099743.53432.a8.

No abstract available.

Cite
Fonarow GC, Abraham WT, Gheorghiade M, et al. Role of beta-blocker therapy in the postmyocardial infarction patient with and without left ventricular dysfunction consensus guideline. Crit Pathw Cardiol. 2003;2(4):239-46doi: 10.1097/01.hpc.0000099743.53432.a8.
Fonarow, G. C., Abraham, W. T., Gheorghiade, M., Cannon, C. P., Sackner-Bernstein, J. D., Udelson, J. E., Konstam, M. A. (2003). Role of beta-blocker therapy in the postmyocardial infarction patient with and without left ventricular dysfunction consensus guideline. Critical pathways in cardiology, 2(4), 239-46. https://doi.org/10.1097/01.hpc.0000099743.53432.a8
Fonarow, Gregg C, et al. "Role of beta-blocker therapy in the postmyocardial infarction patient with and without left ventricular dysfunction consensus guideline." Critical pathways in cardiology vol. 2,4 (2003): 239-46. doi: https://doi.org/10.1097/01.hpc.0000099743.53432.a8
Fonarow GC, Abraham WT, Gheorghiade M, Cannon CP, Sackner-Bernstein JD, Udelson JE, Konstam MA. Role of beta-blocker therapy in the postmyocardial infarction patient with and without left ventricular dysfunction consensus guideline. Crit Pathw Cardiol. 2003 Dec;2(4):239-46. doi: 10.1097/01.hpc.0000099743.53432.a8. PMID: 18340127.
Copy Download .nbib Format: NLM
Efficacy and safety of a unique enteric-coated bicarbonate-buffered pancreatic enzyme replacement therapy in children and adults with cystic fibrosis.

Clinical investigation

Konstan MW, Accurso FJ, Nasr SZ, Ahrens RC, Graff GR.
PMID: 25210613
Clin Investig (Lond). 2013 Aug 01;3(8):723-729. doi: 10.4155/cli.13.62.

BACKGROUND: Pancreatic enzyme replacement therapy (PERT) is used to treat exocrine pancreatic insufficiency in cystic fibrosis.RESULTS/METHODS: Efficacy and safety of a unique enteric-coated (EC) bicarbonate-buffered PERT product (PERTZYESUMMARY: EC-bicarbonate-buffered PERT is effective in treating cystic fibrosis-associated exocrine pancreatic insufficiency.

Cite
Konstan MW, Accurso FJ, Nasr SZ, et al. Efficacy and safety of a unique enteric-coated bicarbonate-buffered pancreatic enzyme replacement therapy in children and adults with cystic fibrosis. Clin Investig (Lond). 2013;3(8):723-729doi: 10.4155/cli.13.62.
Konstan, M. W., Accurso, F. J., Nasr, S. Z., Ahrens, R. C., & Graff, G. R. (2013). Efficacy and safety of a unique enteric-coated bicarbonate-buffered pancreatic enzyme replacement therapy in children and adults with cystic fibrosis. Clinical investigation, 3(8), 723-729. https://doi.org/10.4155/cli.13.62
Konstan, Michael W, et al. "Efficacy and safety of a unique enteric-coated bicarbonate-buffered pancreatic enzyme replacement therapy in children and adults with cystic fibrosis." Clinical investigation vol. 3,8 (2013): 723-729. doi: https://doi.org/10.4155/cli.13.62
Konstan MW, Accurso FJ, Nasr SZ, Ahrens RC, Graff GR. Efficacy and safety of a unique enteric-coated bicarbonate-buffered pancreatic enzyme replacement therapy in children and adults with cystic fibrosis. Clin Investig (Lond). 2013 Aug 01;3(8):723-729. doi: 10.4155/cli.13.62. PMID: 25210613; PMCID: PMC4157687.
Copy Download .nbib Format: NLM
Pseudomonas aeruginosa antimicrobial susceptibility test (AST) results and pulmonary exacerbation treatment responses in cystic fibrosis.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

VanDevanter DR, Heltshe SL, Hilliard JB, Konstan MW.
PMID: 32505525
J Cyst Fibros. 2021 Mar;20(2):257-263. doi: 10.1016/j.jcf.2020.05.008. Epub 2020 Jun 04.

Background Antimicrobial susceptibility testing (AST) of bacterial isolates is a time- and resource-intensive procedure recommended by cystic fibrosis (CF) treatment guidelines for antimicrobial selection for pulmonary exacerbation (PEx) treatment. Methods We studied relationships between Pseudomonas aeruginosa (Pa) isolate AST...

Cite
VanDevanter DR, Heltshe SL, Hilliard JB, et al. Pseudomonas aeruginosa antimicrobial susceptibility test (AST) results and pulmonary exacerbation treatment responses in cystic fibrosis. J Cyst Fibros. 2020;20(2):257-263doi: 10.1016/j.jcf.2020.05.008.
VanDevanter, D. R., Heltshe, S. L., Hilliard, J. B., & Konstan, M. W. (2021). Pseudomonas aeruginosa antimicrobial susceptibility test (AST) results and pulmonary exacerbation treatment responses in cystic fibrosis. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 20(2), 257-263. https://doi.org/10.1016/j.jcf.2020.05.008
VanDevanter, Donald R, et al. "Pseudomonas aeruginosa antimicrobial susceptibility test (AST) results and pulmonary exacerbation treatment responses in cystic fibrosis." Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society vol. 20,2 (2021): 257-263. doi: https://doi.org/10.1016/j.jcf.2020.05.008
VanDevanter DR, Heltshe SL, Hilliard JB, Konstan MW. Pseudomonas aeruginosa antimicrobial susceptibility test (AST) results and pulmonary exacerbation treatment responses in cystic fibrosis. J Cyst Fibros. 2021 Mar;20(2):257-263. doi: 10.1016/j.jcf.2020.05.008. Epub 2020 Jun 04. PMID: 32505525; PMCID: PMC7714709.
Copy Download .nbib Format: NLM
High Prevalence of Sarcopenia in Older Trauma Patients: A Pilot Study.

Journal of clinical medicine

Stassen RC, Reisinger KW, Al-Ali M, Poeze M, Ten Bosch JA, Blokhuis TJ.
PMID: 32610680
J Clin Med. 2020 Jun 29;9(7). doi: 10.3390/jcm9072046.

Sarcopenia is related to adverse outcomes in various populations. However, little is known about the prevalence of sarcopenia in polytrauma patients. Identifying the number of patients at risk of adverse outcome will increase awareness to prevent further loss of...

Cite
Stassen RC, Reisinger KW, Al-Ali M, et al. High Prevalence of Sarcopenia in Older Trauma Patients: A Pilot Study. J Clin Med. 2020;9(7)doi: 10.3390/jcm9072046.
Stassen, R. C., Reisinger, K. W., Al-Ali, M., Poeze, M., Ten Bosch, J. A., & Blokhuis, T. J. (2020). High Prevalence of Sarcopenia in Older Trauma Patients: A Pilot Study. Journal of clinical medicine, 9(7), . https://doi.org/10.3390/jcm9072046
Stassen, Robert C, et al. "High Prevalence of Sarcopenia in Older Trauma Patients: A Pilot Study." Journal of clinical medicine vol. 9,7 (2020). doi: https://doi.org/10.3390/jcm9072046
Stassen RC, Reisinger KW, Al-Ali M, Poeze M, Ten Bosch JA, Blokhuis TJ. High Prevalence of Sarcopenia in Older Trauma Patients: A Pilot Study. J Clin Med. 2020 Jun 29;9(7). doi: 10.3390/jcm9072046. PMID: 32610680; PMCID: PMC7408833.
Copy Download .nbib Format: NLM
Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC study.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Zemanick ET, Konstan MW, VanDevanter DR, Rowe SM, Clancy JP, Odem-Davis K, Skalland M, Mayer-Hamblett N.
PMID: 33573995
J Cyst Fibros. 2021 Nov;20(6):965-971. doi: 10.1016/j.jcf.2021.01.011. Epub 2021 Feb 08.

BACKGROUND: The Characterizing CFTR Modulated Changes in Sweat Chloride and their Association with Clinical Outcomes (CHEC-SC) study is a large epidemiologic study designed to determine the relationship between sweat chloride response and clinical outcomes in people with cystic fibrosis...

Cite
Zemanick ET, Konstan MW, VanDevanter DR, et al. Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC study. J Cyst Fibros. 2021;20(6):965-971doi: 10.1016/j.jcf.2021.01.011.
Zemanick, E. T., Konstan, M. W., VanDevanter, D. R., Rowe, S. M., Clancy, J. P., Odem-Davis, K., Skalland, M., & Mayer-Hamblett, N. (2021). Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC study. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 20(6), 965-971. https://doi.org/10.1016/j.jcf.2021.01.011
Zemanick, Edith T, et al. "Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC study." Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society vol. 20,6 (2021): 965-971. doi: https://doi.org/10.1016/j.jcf.2021.01.011
Zemanick ET, Konstan MW, VanDevanter DR, Rowe SM, Clancy JP, Odem-Davis K, Skalland M, Mayer-Hamblett N. Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC study. J Cyst Fibros. 2021 Nov;20(6):965-971. doi: 10.1016/j.jcf.2021.01.011. Epub 2021 Feb 08. PMID: 33573995; PMCID: PMC8349375.
Copy Download .nbib Format: NLM
Showing 37 to 41 of 41 entries